Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Illumina, Inc. (NASDAQ:ILMN – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Wednesday after Morgan Stanley lowered their price target on the stock from $150.00 to ...

Two U.S. firms, namely PVH Corp. and Illumina, Inc., were added to China's unreliable entity list on Feb. 4. The move could subject the companies to one or multiple measures under Article 10 of the ...

The stock's rise snapped a four-day losing streak.

However, 10 companies defied a broader market optimism, mostly due to a series of stock rating downgrades from investment ...

Shares of Illumina Inc. ILMN shed 5.47% to $104.99 Monday, on what proved to be an all-around favorable trading session for ...

On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...

The Federal Trade Commission's recent challenge to Microsoft's acquisition of Activision has been rejected by a federal court, highlighting the agency's inconsistent and overly broad approach to ...